The European Commission has selected Biovicas project “Clinical validation of the DiviTum™ assay in key European markets” to be funded through the Research and Innovation Framework Program Horizon 2020.
A total of 2 666 proposals were submitted to the first SME (Small Medium Enterprises) Instrument Calls within the European Commission´s R&D Program Horizon 2020. 155 projects from 21 countries were selected and will receive funding of a phase I feasibility study. Each project is supported with €50 000 for a first study and to prepare a Phase 2 application, which, if granted, may result in additional funding.
“We are very pleased that the European Commission has decided to support our project financially. To be chosen as one of the selected projects demonstrates the unique values and potential that DiviTum™ can bring to cancer patients.” says Anders Rylander, CEO Biovica.
The goal of the project is to bring further evidence of DiviTum™ as a predictive and monitoring tool in solid tumours, enabling better clinical decisions for cancer therapy and drug development, resulting in a more optimal treatment for patients. The project aims to initiate extended clinical studies with selected institutes, partners and stakeholders running clinical trials in key European markets and with access to bio-banks.